Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease

被引：52
|
作者：
Mizuno, Y
Yanagisawa, N
Kuno, S
Yamamoto, M
Hasegawa, K
Origasa, H
Kowa, H
机构：
[1] Juntendo Univ, Sch Med, Dept Neurol, Bunkyo Ku, Tokyo 1138421, Japan
[2] Kanto Rosai Hosp, Kawasaki, Kanagawa, Japan
[3] Natl Utano Hosp, Ctr Neurol Dis, Clin Res Sect, Kyoto, Japan
[4] Kagawa Prefectural Cent Hosp, Dept Neurol, Takamatsu, Kagawa, Japan
[5] Sagamihara Natl Hosp, Dept Neurol, Sagamihara, Kanagawa, Japan
[6] Toyama Med & Pharmaceut Univ, Fac Med, Div Biostat, Toyama, Japan
[7] Kitasato Univ, Tokyo, Japan
来源：
MOVEMENT DISORDERS | 2003年 / 18卷 / 10期
关键词：
Parkinson's disease; pramipexole; bromocriptine; levodopa; drug comparison; randomized controlled trial (RCT);
D O I：
10.1002/mds.10508
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
We compared the efficacy and safety of pramipexole (PPX) with placebo in the treatment of advanced Parkinson's disease (PD) as an adjunct to levodopa. A bromocriptine (1311) group was included to enable determination of the noninferiority of PPX relative to 1311 as the standard treatment. (C) 2003 Movement Disorder Society.
引用
收藏
页码：1149 / 1156
页数：8
相关论文
共 50 条
  • [21] Rotigotine transdermal patch in early Parkinson's disease: A randomized, double-blind, controlled study versus placebo and ropinirole
    Giladi, Nir
    Boroojerdi, Babak
    Korczyn, Amos D.
    Burn, David J.
    Clarke, Carl E.
    Schapira, Anthony Hn.
    MOVEMENT DISORDERS, 2007, 22 (16) : 2398 - 2404
  • [22] A Double-Blind, Randomized, Placebo-Controlled Trial of Bumetanide in Parkinson's Disease
    Damier, Philippe
    Degos, Bertrand
    Castelonovo, Giovanni
    Anheim, Mathieu
    Benatru, Isabelle
    Carriere, Nicolas
    Colin, Olivier
    Defebvre, Luc
    Deverdal, Marie
    Eusebio, Alexandre
    Ferrier, Vanessa
    Giordana, Caroline
    Houeto, Jean-Luc
    Le Dily, Severine
    Mongin, Marie
    Thiriez, Claire
    Tranchant, Christine
    Ravel, Denis
    Corvol, Jean-Christophe
    Rascol, Olivier
    Ben Ari, Yehezkel
    MOVEMENT DISORDERS, 2024, 39 (03) : 618 - 622
  • [23] Double-blind, single-dose, cross-over study of the effects of pramipexole, pergolide, and placebo on rest tremor and UPDRS part III in Parkinson's disease
    Navan, P
    Findley, LJ
    Jeffs, JAR
    Pearce, RKB
    Bain, PG
    MOVEMENT DISORDERS, 2003, 18 (02) : 176 - 180
  • [24] Antiparkinsonian drug-induced sleepiness: a double-blind placebo-controlled study of L-dopa, bromocriptine and pramipexole in healthy subjects
    Micallef, Joelle
    Rey, Marc
    Eusebio, Alexandre
    Audebert, Christine
    Rouby, Frank
    Jouve, Elisabeth
    Tardieu, Sophie
    Blin, Oliver
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 67 (03) : 333 - 340
  • [25] A Randomized, Double-Blind, Controlled Phase II Study of Foliglurax in Parkinson's Disease
    Rascol, Olivier
    Medori, Rossella
    Baayen, Corine
    Such, Pedro
    Meulien, Didier
    MOVEMENT DISORDERS, 2022, 37 (05) : 1088 - 1093
  • [26] Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double blind, placebo controlled, randomised, multicentre study
    Pinter, MM
    Pogarell, O
    Oertel, WH
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1999, 66 (04) : 436 - 441
  • [27] The Effects of Rasagiline on Cognitive Deficits in Parkinson's Disease Patients Without Dementia: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study
    Hanagasi, Hasmet A.
    Gurvit, Hakan
    Unsalan, Pinar
    Horozoglu, Hilal
    Tuncer, Nese
    Feyzioglu, Aynur
    Gunal, Dilek Ince
    Yener, Gorsev G.
    Cakmur, Raif
    Sahin, Huseyin A.
    Emre, Murat
    MOVEMENT DISORDERS, 2011, 26 (10) : 1851 - 1858
  • [28] Pingchan Granule for Motor Symptoms and Non-Motor Symptoms of Parkinson's Disease: A Randomized, Double-Blind, Placebo-Controlled Study
    Gu, Si-Chun
    Ye, Qing
    Wang, Chang-De
    Zhao, Shao-Rong
    Zhou, Jie
    Gao, Chen
    Zhang, Yu
    Liu, Zhen-Guo
    Yuan, Can-Xing
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [29] Opicapone OCEAN study in Parkinson's: design of a randomized double-blind placebo-controlled trial
    Chaudhuri, K. Ray
    Odin, P.
    Ferreira, J.
    Antonini, A.
    Rascol, O.
    Kurtis, M.
    Storch, A.
    Bannister, K.
    Costa, R.
    Magalhaes, D.
    Rocha, J. F.
    Soares-da-silva, P.
    EUROPEAN JOURNAL OF NEUROLOGY, 2021, 28 : 902 - 902
  • [30] A double-blind, placebo-controlled and longitudinal study of riluzole in early Parkinson's disease
    Jankovic, J
    Hunter, C
    PARKINSONISM & RELATED DISORDERS, 2002, 8 (04) : 271 - 276
12345